Swiss pharmaceutical giant Novartis has unveiled a $23 billion investment plan to build seven new facilities in the United States and expand several existing ones over the next five years. The announcement follows President Donald Trump’s pledge to impose steep tariffs on imported pharmaceutical products and medications. In a press release, the company said it will expand its U.S. manufacturing footprint across 10 sites, including the construction of seven brand-new facilities in the latest win for the 47th president.
“Today, Novartis, a leading global innovative medicines company, announced a planned $23 billion investment over 5 years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the United States,” the European firm announced in a press release. With its new manufacturing capacity, Novartis can now produce all of its key medicines entirely in the United States.
The plan is expected to create approximately 1,000 new jobs, with thousands more positions relocating to the U.S., bringing the total impact to over 4,000 American jobs. As part of the investment, Novartis will establish a biomedical research innovation hub in San Diego, California. Over the next five years, the company also plans to construct four additional manufacturing facilities in yet-to-be-announced states. Three of these will focus on producing biologic drug substances, drug products, device assembly, and packaging, while the fourth will manufacture chemical drug substances, oral solid dosage forms, and packaging.
The expansion will include the construction of two new radioligand therapy (RLT) manufacturing facilities in Florida and Texas, while three existing facilities in Indiana, New Jersey, and California will be updated. “This new investment will bring internal manufacturing of the company’s siRNA technology to the US for the first time and reflects a commitment to increase US manufacturing across its main therapeutic areas: oncology, immunology, neuroscience, and cardiovascular, renal and metabolic. With new manufacturing capacity, Novartis will be able to produce 100% of its key medicines end-to-end in the US, a significant increase from current levels,” the press release added.
“As a Swiss-based company with a significant presence in the US, these investments will enable us to fully bring our supply chain and key technology platforms into the US to support our strong US growth outlook. These investments also reflect the pro-innovation policy and regulatory environment in the US that supports our ability to find the next medical breakthroughs for patients,” said Vas Narasimhan, CEO of Novartis. “We are prepared for shifts in the external environment and fully confident in our 2025 guidance, mid- to long-term sales growth outlook and 2027 core margin guidance of 40 percent +.”